Clinical Trial Update: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mesna to prevent doxorubicin-induced plasma protein oxidation and TNF-α release in patients with breast cancer or non-Hodgkin lymphoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-hodgkin Lymphoma

Drugs mentioned

• MESNA (MESNA)

Snippet

Sponsor: Mara Chambers | Conditions: Breast Cancer, Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-24